This study is in progress, not accepting new patients
Study of AMV564 in Patients With AML
Acute Myeloid Leukemia AML treatment relapsed refractory phase 1 Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Pembrolizumab AMV564 AMV564 in combination with pembrolizumab
Lead Scientist at UCSF
- Aaron Logan
Dr. Aaron Logan is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Amphivena Therapeutics, Inc.
- Phase 1
- Study Type
- Last Updated